Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update

Gossamer Bio, Inc. (NASDAQ:GOSS) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 948,623 shares, a decrease of 98.9% from the August 31st total of 82,633,317 shares. Currently, 33.7% of the shares of the company are short sold. Based on an average daily volume of 186,993 shares, the days-to-cover ratio is currently 5.1 days.

Hedge Funds Weigh In On Gossamer Bio

A number of large investors have recently made changes to their positions in the company. Corient Private Wealth LP boosted its stake in shares of Gossamer Bio by 41.3% in the 2nd quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock valued at $927,000 after purchasing an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in Gossamer Bio by 1,289.4% in the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock worth $267,000 after acquiring an additional 1,469,175 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Gossamer Bio during the second quarter worth about $65,000. Hhlr Advisors LTD. purchased a new stake in Gossamer Bio in the 2nd quarter valued at $819,000. Finally, ARCH Venture Management LLC purchased a new position in shares of Gossamer Bio in the 2nd quarter worth approximately $1,326,004. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Trading Down 6.0%

NASDAQ:GOSS traded down $0.66 during trading hours on Friday, hitting $10.28. 35,158 shares of the company traded hands, compared to its average volume of 235,037. The stock has a market capitalization of $30.11 million, a price-to-earnings ratio of -0.18 and a beta of 2.00. Gossamer Bio has a twelve month low of $9.10 and a twelve month high of $309.60. The firm has a 50-day moving average of $13.02 and a 200 day moving average of $19.53.

Wall Street Analyst Weigh In

GOSS has been the topic of a number of recent research reports. Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a research note on Tuesday, July 28th. Wall Street Zen lowered shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Weiss Ratings raised Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Finally, HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $256.00.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for pulmonary and inflammatory diseases. The company’s research is centered on therapeutic areas with significant unmet medical needs, including pulmonary hypertension and other immune-mediated conditions.

Gossamer Bio’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary arterial hypertension and pulmonary vascular remodeling.